Troy E. Wilson, Ph.D., J.D., is the President and Chief Executive Officer at Kura Oncology, Inc., a biopharmaceutical company focused on developing innovative cancer therapies. Dr. Wilson has a robust background in both the scientific and legal fields, which uniquely positions him to lead Kura Oncology. He earned his Ph.D. in Biochemistry from the University of California, Berkeley, and his J.D. from Stanford Law School. Prior to joining Kura Oncology, Dr. Wilson held various leadership positions in the biotech industry, including serving as Senior Vice President and Chief Scientific Officer at Ambit Biosciences, where he played a pivotal role in the development of quizartinib, a drug candidate for the treatment of acute myeloid leukemia. At Kura Oncology, Dr. Wilson has been instrumental in steering the company's strategic direction and advancing its pipeline of novel cancer therapies. Under his leadership, Kura has made significant progress in clinical development, notably with their lead candidate, tipifarnib, which is being evaluated for the treatment of head and neck squamous cell carcinoma. Dr. Wilson's vision for Kura Oncology is to transform the treatment landscape for cancer patients by targeting hard-to-treat mutations and developing therapies that address unmet medical needs. His dual expertise in biochemistry and law allows him to navigate the complex regulatory and scientific challenges inherent in drug development. In addition to his role at Kura Oncology, Dr. Wilson is actively involved in the broader scientific community. He has authored numerous publications in peer-reviewed journals and is a frequent speaker at industry conferences. His contributions to the field of oncology have been recognized with several awards and honors. Dr. Wilson's leadership, combined with his scientific and legal acumen, continues to drive Kura Oncology forward as it seeks to bring new hope to cancer patients worldwide.